Novel polypeptide and method for producing L-leucine using the same

A mutant polypeptide with altered isopropylmalate synthase activity addresses feedback inhibition in L-leucine biosynthesis, achieving significantly higher production yields.

JP7584536B2Active Publication Date: 2024-11-15CJ CHEILJEDANG CORP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022562152
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-20
Filing Date
2021-05-13
Publication Date
2024-11-15
Estimated Expiration
2041-05-13

AI Technical Summary

Technical Problem

The biosynthesis of L-leucine is hindered by feedback inhibition from the final product L-leucine or its derivatives, limiting industrial production yields in existing methods.

Method used

A mutant polypeptide with altered isopropylmalate synthase activity, specifically replacing the 247th proline residue with another amino acid, is used to enhance enzyme activity and reduce feedback inhibition, thereby increasing L-leucine production.

Benefits of technology

The mutant polypeptide enhances L-leucine production by up to 150% compared to wild-type strains, with improved enzyme activity and reduced feedback inhibition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584536000001
    Figure 0007584536000001
  • Figure 0007584536000002
    Figure 0007584536000002
  • Figure 0007584536000003
    Figure 0007584536000003
Patent Text Reader

Abstract

The present application relates to a novel mutant polypeptide having isopropyl malate synthase activity and a method for producing L-leucine using the same. In one example, the mutant polypeptide can be used to produce L-leucine in high yield.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Cross-reference to related applications This application claims the benefit of priority based on Korean Patent Application No. 10-2020-0060578 filed on May 20, 2020, and all contents disclosed in the documents of this Korean patent application are incorporated herein by reference.

[0002] The present application relates to novel mutant polypeptides having isopropylmalate synthase activity; polynucleotides encoding the same; vectors comprising said polynucleotides; microorganisms comprising said mutant polypeptides, said polynucleotides, said vectors, or combinations thereof; and methods for culturing said microorganisms to produce L-leucine. [Background technology]

[0003] L-amino acids are industrially produced by fermentation using amino acid-producing bacteria belonging to the coryneform bacteria or Enterobacteriaceae family that have the ability to produce L-amino acids. These amino acid-producing bacteria are strains isolated from nature to improve productivity, artificial mutants of the strains, or recombinants in which L-amino acid biosynthetic enzymes have been enhanced by genetic recombination.

[0004] Among L-amino acids, L-leucine is an essential amino acid that is widely used in medicines, food, and feed additives, industrial chemicals, and is an expensive amino acid that is mainly produced using microorganisms. L-leucine is mainly produced by fermentation using Escherichia or Corynebacterium microorganisms, and is known to be biosynthesized from pyruvic acid through multiple steps to 2-ketoisocaproate, a precursor. However, the enzymes involved in the biosynthesis of L-leucine are subject to feedback inhibition by the final product, L-leucine, or its derivatives, making it difficult to mass-produce L-leucine industrially.

[0005] Therefore, the inventors of the present application confirmed that a mutant strain obtained by mutating a specific position of isopropyl malate synthase can be used for high-yield L-leucine production by optimizing the enzyme activity, and thus completed the present invention. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] US2018-0251772A1 Summary of the Invention [Problem to be solved by the invention]

[0007] The present application provides a mutant polypeptide having isopropylmalate synthase activity, in which the 247th proline amino acid residue in the amino acid sequence of SEQ ID NO:1 is substituted with an amino acid residue other than proline.

[0008] The present application provides polynucleotides encoding the mutant polypeptides.

[0009] The present application provides a vector comprising the polynucleotide.

[0010] The present application provides a microorganism comprising one or more selected from the group consisting of the mutant polypeptide, the polynucleotide, and a vector comprising the polynucleotide.

[0011] The present application provides a method for producing L-leucine, comprising the step of culturing said microorganism in a medium.

[0012] The present application provides a composition for producing L-leucine, comprising one or more selected from the group consisting of the mutant polypeptide, a polynucleotide encoding the mutant polypeptide, a vector comprising the polynucleotide, and the microorganism (e.g., a microorganism (recombinant cell) comprising the mutant polypeptide of the present application, the polynucleotide of the present application, and / or the vector of the present application).

[0013] The present application provides uses of the mutant polypeptides, polynucleotides encoding the mutant polypeptides, vectors comprising the polynucleotides, and the microorganisms (e.g., microorganisms (recombinant cells) comprising the mutant polypeptides of the present application, the polynucleotides of the present application, and / or the vectors of the present application) for the production of one or more L-leucine selected from the group consisting of the mutant polypeptides of the present application, the polynucleotides of the present application, and / or the vectors of the present application. [Means for solving the problem]

[0014] One aspect of the present application provides a mutant polypeptide (or variant) having isopropyl malate synthase activity, in which the amino acid residue at or corresponding to the 247th amino acid residue from the N-terminus in the amino acid sequence of the isopropyl malate synthase protein of SEQ ID NO: 1 is substituted with another amino acid residue.

[0015] As used herein, "isopropylmalate synthase (2-isopropylmalate synthase, α-isopropylmalate synthase)" refers to an enzyme that catalyzes the condensation of 2-ketoisovalerate (3-methyl-2-oxobutanoate, 2-exoisovalerate) with the acetyl group of acetyl-CoA to convert it into isopropylmalate (2-isopropylmalate, 3-carboxy-3-hydroxy-4-methylpentanoate), which is one of the precursors of L-leucine. The isopropylmalate synthase may be any enzyme having the conversion activity, regardless of the microorganism from which it is derived, and may be, for example, an enzyme derived from a microorganism of the genus Corynebacterium.

[0016] The isopropyl malate synthase may include or consist of the amino acid sequence of SEQ ID NO: 1. In addition, regardless of the origin of the microorganism, a polypeptide having at least 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 92% or more, 94% or more, 96% or more, 98% or more, 99% or more, 99.5% or more, or 99.8% or more homology with the amino acid sequence of SEQ ID NO: 1 and an enzyme having the same or corresponding conversion activity as isopropyl malate synthase, a polypeptide having an amino acid sequence in which a part of the amino acid sequence of SEQ ID NO: 1 is deleted, modified, substituted, or added may also be included within the scope of the present application as the isopropyl malate synthase.

[0017] In other words, even if the present application describes "a polypeptide (or protein) comprising an amino acid sequence set forth in a particular SEQ ID NO" or "a polypeptide (or protein) consisting of an amino acid sequence set forth in a particular SEQ ID NO," a polypeptide (or protein) having an amino acid sequence in which a portion of the sequence has been deleted, modified, substituted or added can also be used as a protein or polypeptide to be mutated in the present application, so long as it has the same or corresponding activity as a polypeptide (or protein) consisting of the amino acid sequence of the SEQ ID NO. For example, a polypeptide having the same or corresponding activity as a "polypeptide consisting of the amino acid sequence of SEQ ID NO: 1" can belong to the "polypeptide consisting of the amino acid sequence of SEQ ID NO: 1."

[0018] The amino acid sequence of the isopropyl malate synthase and the nucleotide sequence of the gene encoding isopropyl malate synthase can be easily obtained from databases known in the art, such as the National Center for Biotechnology Information (NCBI) and the DNA Data Bank of Japan (DDBJ).

[0019] As used herein, a polynucleotide or polypeptide "comprising a specific nucleic acid sequence (base sequence) or amino acid sequence" may mean that the polynucleotide or polypeptide consists of or essentially contains the specific nucleic acid sequence (base sequence) or amino acid sequence, and may be interpreted as including a sequence in which a mutation (deletion, substitution, modification, and / or addition) has been added to the specific nucleic acid sequence (base sequence) or amino acid sequence within the scope of maintaining the original function and / or intended function of the polynucleotide or polypeptide (or not excluding the mutation). In one example, a polynucleotide or polypeptide "comprising a specific nucleic acid sequence (base sequence) or amino acid sequence" can mean that the polynucleotide or polypeptide (i) consists of or essentially includes the specific nucleic acid sequence (base sequence) or amino acid sequence, or (ii) consists of or essentially includes a nucleic acid sequence or amino acid sequence that has 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 98% or more, 99.5% or more, or 99.9% or more homology to the specific nucleic acid sequence (base sequence) or amino acid sequence, and maintains its original function and / or intended function.

[0020] In the present specification, the amino acid sequence of isopropyl malate synthase derived from wild-type Corynebacterium glutamicum (e.g., ATCC13032) is shown in SEQ ID NO: 1, and the base sequence of the leuA gene encoding isopropyl malate synthase derived from a wild-type strain is shown in SEQ ID NO: 2. Although isopropyl malate synthase is shown to be composed of 616 amino acids in SEQ ID NO: 1, in some literature, it is known to be composed of 581 amino acids by indicating 35 amino acids after the translation initiation codon, and the amino acid sequence of isopropyl malate synthase composed of 581 amino acids is shown in SEQ ID NO: 16. Isopropyl malate synthase composed of 581 amino acids may be included in the scope of the present application as the isopropyl malate synthase, and in such a case, the 247th position may be interpreted as the 212th position and may be included in the scope of the present application.

[0021] In one embodiment, the mutant polypeptide has an amino acid sequence of SEQ ID NO:1 in which the arginine amino acid residue at position 558 (or a position corresponding thereto) is replaced with an amino acid residue other than arginine;

[0022] The glycine amino acid residue at position 561 (or a position corresponding thereto) of the amino acid sequence of SEQ ID NO:1 may be substituted with an amino acid residue other than glycine, or may be further mutated by all of these.

[0023] In one example, in the case of isopropyl malate synthase consisting of 581 amino acids of SEQ ID NO: 16, the 558th position may be interpreted as the 523rd position, and the 561st position may be interpreted as the 526th position, and may be included within the scope of the present application.

[0024] As used herein, "homology" refers to the percentage of identity between two polynucleotide or polypeptide moieties. The homology between sequences from one moiety to another can be determined by known techniques. For example, homology can be determined by aligning sequence information and directly aligning parameters such as score, identity, and similarity between two polynucleotide molecules or two polypeptide molecules using a readily available computer program. The computer program can be BLAST (NCBI), CLC Main Workbench (CLC bio), MegAlignTM (DNASTAR Inc), etc. Alternatively, the homology between polynucleotides can be determined by hybridizing the polynucleotides under conditions that form a stable double strand between the homologous regions, and then degrading them with a single-strand specific nuclease to confirm the size of the degraded fragments.

[0025] In one embodiment, a mutant polypeptide having isopropylmalate synthase activity can be provided, in which the proline amino acid residue at position 247 (or a position corresponding thereto) in the amino acid sequence of SEQ ID NO:1 is substituted with an amino acid residue other than proline.

[0026] Another embodiment can provide a mutant polypeptide having isopropyl synthase activity, in which the 212th amino acid residue, proline, in the amino acid sequence of SEQ ID NO: 16 is substituted with an amino acid residue other than proline.

[0027] In this specification, "the amino acid sequence of SEQ ID NO: __" may be used in the same sense as "the amino acid sequence of SEQ ID NO: __ from the N-terminus of a polypeptide consisting of (or consisting of) the amino acid sequence of SEQ ID NO: __."

[0028] The amino acids other than proline can include arginine, alanine, leucine, isoleucine, valine, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, lysine, histidine, aspartic acid, and glutamic acid.

[0029] In one embodiment, the mutant polypeptide may have a proline at position 247 (or a position corresponding thereto) of the amino acid sequence of SEQ ID NO:1 substituted with a cysteine.

[0030] According to one embodiment, the mutant polypeptide may comprise or consist of the amino acid sequence of SEQ ID NO:3.

[0031] In one example, the mutant polypeptide may be one in which the amino acid residue at the position corresponding to position 247 (position 212 in the case of SEQ ID NO: 16) in the amino acid sequence of a polypeptide having 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 92% or more, 94% or more, 96% or more, 98% or more, or 99% or more, 99.5% or more, or 99.8% or more homology to the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) is replaced with another amino acid residue.

[0032] In one embodiment, the mutant polypeptide may have an amino acid sequence in which proline at position 247 in the amino acid sequence of SEQ ID NO: 1 (or proline at position 212 in the amino acid sequence of SEQ ID NO: 16) or a corresponding position is replaced with another amino acid, thereby increasing L-leucine production activity compared to a polypeptide containing the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16).

[0033] According to one embodiment, a mutant polypeptide having an amino acid sequence of SEQ ID NO: 1 or a polypeptide having 70% or more, 80% or more, 85% or more, 90% or more, 92% or more, 94% or more, 96% or more, 98% or more, or 99% or more homology to the amino acid sequence of SEQ ID NO: 1 in which the amino acid residue at proline 247 or a corresponding position thereto is replaced with another amino acid residue may have isopropyl malate synthase activity. The other amino acid residue may mean another type of amino acid residue other than the amino acid (e.g., proline) that was present at the position (at position 247 or a corresponding position in the amino acid sequence of SEQ ID NO: 1) before the replacement.

[0034] In one embodiment, the mutant polypeptide may have an amino acid residue at proline 247 (or 212) or a corresponding position in the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) replaced with another amino acid residue, thereby increasing L-leucine production activity compared to isopropyl malate synthase derived from a wild-type strain (e.g., isopropyl malate synthase including (or consisting of) the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 16).

[0035] In one specific example, the mutant polypeptide may have an amino acid residue at proline 247 (or 212) or a corresponding position in the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) replaced with another amino acid residue, thereby increasing the enzymatic activity of isopropyl malate synthase compared to isopropyl malate synthase derived from a wild-type strain (e.g., isopropyl malate synthase consisting of the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16)).

[0036] As used herein, "increased isopropyl malate synthase activity" means increased activity in converting to isopropyl malate, and thus a mutant polypeptide according to one embodiment may have a higher level of activity in converting to isopropyl malate than a polypeptide having isopropyl malate synthase activity comprising the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16).

[0037] In the present specification, the term "increasing activity" can be used in combination with the term "enhancing activity." Since isopropyl malate is one of the precursors of L-leucine, when the mutant polypeptide according to one embodiment is used, it is possible to produce L-leucine at a higher level as a result, compared to a polypeptide having the activity of isopropyl malate synthase comprising the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16).

[0038] The activity of converting to isopropyl malate can be directly confirmed by measuring the level of isopropyl malate produced, or indirectly confirmed by measuring the level of CoA produced. The enzyme activity of isopropyl malate synthase can be measured by a known method, for example, the method described in the literature [Kohlhaw et al. (Methods in Enzymology 166:423-9 (1988))], and the activity of isopropyl malate synthase enzyme can be measured by measuring the change in absorbance at 412 nm due to thionitrobenzoate (TNB) formed from DTNB (5,5'-dithiobis-(2-nitrobenzoic acid), Ellman's reagent) by reduction using the produced CoA.

[0039] In one embodiment, the mutant polypeptide has the proline at position 247 (or 212) of the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) or a corresponding position replaced with another amino acid, and can reduce feedback inhibition by L-leucine and / or its derivatives compared to isopropyl malate synthase derived from a wild-type strain (e.g., isopropyl malate synthase consisting of the amino acid sequence of SEQ ID NO: 1).

[0040] As used herein, "feedback inhibition" means that the end product of an enzyme system inhibits an early reaction of the enzyme system. For example, the feedback inhibition may be the inhibition of the activity of isopropylmalate synthase, which mediates the first step of the biosynthetic pathway of L-leucine and / or its derivatives. Thus, when the feedback inhibition of isopropylmalate synthase is reduced (or released), the productivity of L-leucine can be increased compared to the case where the feedback inhibition is not reduced.

[0041] As used herein, the term "derivative" may refer to a compound known to be capable of inducing feedback inhibition in relation to the biosynthesis of L-leucine, which is the final product of the present invention, thereby inhibiting the ability of a microorganism to produce L-leucine, and may include, for example, isoleucine, terleucine, norleucine, and / or cycloleucine.

[0042] According to one specific example, the mutant polypeptide may be additionally mutated at a position other than position 247 (or position 212) in the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) to synergistically increase one or more effects selected from the group consisting of: (1) increased L-leucine production activity; (2) increased enzyme activity of isopropyl malate synthase; and (3) reduced feedback inhibition by L-leucine and / or its derivatives.

[0043] According to one specific example, the mutant polypeptide may additionally contain a mutation that can have one or more effects selected from the group consisting of: (1) increased L-leucine production activity; (2) increased enzyme activity of isopropyl malate synthase; and (3) reduced feedback inhibition by L-leucine and / or its derivatives.

[0044] The mutant polypeptide comprises: In the amino acid sequence of SEQ ID NO: 1, the arginine amino acid residue at position 558 (or a position corresponding thereto) is replaced with an amino acid residue other than arginine; The glycine amino acid residue at position 561 (or a position corresponding thereto) of the amino acid sequence of SEQ ID NO:1 may be substituted with an amino acid residue other than glycine, or may be further mutated by all of these.

[0045] The mutant polypeptide comprises: In the amino acid sequence of SEQ ID NO: 16, the arginine amino acid residue at position 523 (or a position corresponding thereto) is replaced with an amino acid residue other than arginine; The glycine amino acid residue at position 526 (or a position corresponding thereto) of the amino acid sequence of SEQ ID NO: 16 may be substituted with an amino acid residue other than glycine, or may be further mutated by all of these.

[0046] The amino acids other than arginine may include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, lysine, histidine, aspartic acid, and glutamic acid, and the amino acids other than glycine may include, but are not limited to, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine, arginine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, lysine, histidine, aspartic acid, and glutamic acid.

[0047] According to one embodiment, the amino acid other than arginine may be histidine.

[0048] According to one embodiment, the amino acid other than glycine may be aspartic acid.

[0049] In one embodiment, the mutant polypeptide comprises: In the amino acid sequence of SEQ ID NO: 1, the 558th arginine amino acid residue is replaced with a histidine amino acid residue; In the amino acid sequence of SEQ ID NO: 1, the 561st glycine amino acid residue is replaced with an aspartic acid amino acid residue, or All of these may be further mutated.

[0050] According to one embodiment, the mutant polypeptide may comprise or consist of the amino acid sequence of SEQ ID NO:5.

[0051] In one embodiment, a mutant polypeptide in which the amino acid residue at position 247 (or 212) in the amino acid sequence of SEQ ID NO:1 (or SEQ ID NO:16) is replaced with an amino acid residue other than proline,

[0052] A mutant polypeptide further mutated by substituting the 558th (or 523rd) arginine amino acid residue with an amino acid residue other than arginine, substituting the 561st (or 526th) glycine amino acid residue with an amino acid residue other than glycine in the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16), or by all of these. (i) an isopropyl malate synthase derived from a wild-type strain (e.g., an isopropyl malate synthase having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 16), or (ii) a mutant polypeptide in which the proline amino acid residue at position 247 (or position 212) in the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) is replaced with an amino acid residue other than proline, One or more effects selected from the group consisting of the following (1) to (3) may be increased: (1) Increased L-leucine production activity; (2) increased enzyme activity of isopropyl malate synthase; and (3) Reduction of feedback inhibition by L-leucine and / or its derivatives.

[0053] According to one embodiment, by combining mutations in which the amino acids at positions 247, 558, and / or 561 (or 212, 523, and / or 526) in the amino acid sequence of SEQ ID NO:1 (or SEQ ID NO:16) are replaced with other types of amino acids, the mutant polypeptide according to one embodiment may have one or more effects selected from the group consisting of the following (1) to (3) that are synergistically increased: (1) Increased L-leucine production activity; (2) increased enzyme activity of isopropyl malate synthase; and (3) Reduction of feedback inhibition by L-leucine and / or its derivatives.

[0054] The effects (1) to (3) are as described above.

[0055] In another embodiment, a polynucleotide encoding the mutant polypeptide can be provided. As used herein, the term "polynucleotide" refers to a nucleotide polymer in which nucleotide monomers are linked in a long chain pattern by covalent bonds, and may refer to a DNA or RNA chain of a certain length or more, more specifically, to a polynucleotide fragment encoding the mutant.

[0056] The mutant polypeptide is as described above.

[0057] The polynucleotide may include, without limitation, a polynucleotide sequence that encodes a variant polypeptide of the present application.

[0058] In one example, the polynucleotide may be a polynucleotide encoding a polypeptide in which the proline amino acid residue at position 247 (or position 212) in the amino acid sequence of SEQ ID NO:1 (or SEQ ID NO:16) is replaced with an amino acid residue other than proline, or a polynucleotide encoding a polypeptide having 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 92% or more, 94% or more, 96% or more, 98% or more, 99% or more, 99.5% or more, or 99.8% or more homology to the amino acid sequence of SEQ ID NO:1 (or SEQ ID NO:16) and in which the amino acid residue at position 247 (or position 212) in the amino acid sequence of SEQ ID NO:1 (or SEQ ID NO:16) is replaced with another amino acid residue, or a polypeptide in which a part of the sequence has been deleted, modified, substituted, or added.

[0059] According to one embodiment, the polynucleotide can hybridize under stringent conditions with a probe that can be prepared from a known gene sequence, for example, a complementary sequence to the entire or partial polynucleotide sequence, and can include, without limitation, a probe containing a sequence corresponding to a sequence encoding a protein mutant in which the amino acid at position 247 (or position 212) of the amino acid sequence of SEQ ID NO: 1 (or SEQ ID NO: 16) or a position corresponding thereto is replaced with another amino acid. The "stringent conditions" refer to conditions under which so-called specific hybridization is formed and non-specific hybridization is not formed. For example, the conditions include conditions under which genes with high homology hybridize with each other and genes with a homology of 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 92% or more, 94% or more, 96% or more, 98% or more, or 99% or more, 99.5% or more, or 99.8% or more hybridize with each other, but genes with lower homology do not hybridize with each other, and conditions under which washing is performed once, specifically 2 to 3 times, at a salt concentration and temperature equivalent to the washing conditions of normal Southern hybridization, which are 60°C, 1 x SSC, 0.1% SDS, specifically 60°C, 0.1 x SSC, 0.1% SDS, more specifically 68°C, 0.1 x SSC, 0.1% SDS (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001)).

[0060] The probe used in the hybridization may be a part of the complementary sequence of the base sequence. Such a probe may be prepared by PCR using an oligonucleotide based on a known sequence as a primer and a gene fragment containing such a base sequence as a template. For example, a gene fragment having a length of about 300 bp may be used as the probe. More specifically, when a probe having a length of about 300 bp is used, the washing conditions for hybridization may be 50°C, 2×SSC, and 0.1% SDS.

[0061] According to one embodiment, the polynucleotide may comprise the base sequence of SEQ ID NO: 4 or SEQ ID NO: 6, or may consist of the base sequence of SEQ ID NO: 4 or SEQ ID NO: 6, and polynucleotides that can be translated into a mutant polypeptide according to one embodiment due to codon degeneracy are also included within the scope of the present application.

[0062] Another aspect may provide a vector comprising the polynucleotide.

[0063] As used herein, a "vector" refers to any medium for cloning and / or transferring bases into a host cell. A vector can be a replican to which other DNA fragments can be attached to effect replication of the attached fragment. A "replicon" refers to any genetic unit (e.g., plasmid, phage, cosmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo, i.e., capable of self-regulating replication.

[0064] In one example, a vector can be a DNA construct containing a polynucleotide sequence encoding a protein of interest operably linked to a suitable regulatory sequence to allow the expression of said protein of interest in a suitable host. The regulatory sequence can include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. After being transformed into a suitable host cell, the vector can replicate and function independently of the host genome, or can be integrated into the genome itself.

[0065] As used herein, "operably linked" means that the gene sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the polypeptide.

[0066] The vector is not particularly limited as long as it can replicate in a host cell, and any vector known in the art can be used. For example, the vector can be a plasmid, cosmid, virus, or bacteriophage in a natural or recombinant state, and MBL3, MBL4, IXII, ASHII, APII, t10, t11, pWE15, M13, λEMBL3, λEMBL4, λFIXII, λDASHII, λZAPII, λgt10, λgt11, Charon4A, and / or Charon21A can be used as a phage vector or cosmid vector, and pDC series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, pDZ series, and / or pET series can be used as a plasmid vector. For example, pDC, pDCM2, pCR2.1, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118 and / or pCC1BAC vectors and the like can be used.

[0067] In another aspect, a microorganism (or recombinant cell) can be provided that contains one or more selected from the group consisting of the mutant polypeptide, a polynucleotide encoding the mutant polypeptide, and a vector containing the polynucleotide.

[0068] The mutant polypeptide, polynucleotide and vector are as described above.

[0069] The microorganism (or recombinant cell) may additionally contain a mutation that increases L-leucine production, and the position of the mutation and / or the type of gene to be mutated may be any that increases L-leucine production, without limitation.

[0070] The microorganism (or recombinant cell) may further include a mutation that enhances the activity of an enzyme involved in the biosynthesis of L-leucine. The activity of the enzyme is enhanced as described above.

[0071] The microorganism (recombinant cell) can be any cell that can be transformed without any limitation.

[0072] The microorganism (or recombinant cell) may have an ability to produce L-leucine. The microorganism (or recombinant cell) may have an ability to produce L-leucine that is not possessed by the cell before recombination, the parent strain, and / or the wild-type strain, or may have an improved ability to produce L-leucine.

[0073] The microorganism (or recombinant cell) may be one in which the amino acid sequence corresponding to isopropyl malate synthase has been mutated to increase its activity compared to the cell before the recombinant cell, the parent strain, and / or the wild-type strain, or the feedback inhibition of L-leucine and its derivatives has been relieved, or both the enzyme activity and the feedback inhibition have been increased.

[0074] The microorganism (or recombinant cell) may be one in which a polynucleotide according to an embodiment is integrated into a chromosome, for example, a polynucleotide according to an embodiment may replace a native leuA gene (encoding isopropyl malate synthase) at a genetic site in a chromosome, or may be integrated into an additional genetic site.

[0075] As used herein, "having L-leucine producing ability" refers to cells and / or microorganisms that naturally have leucine producing ability, or cells and / or microorganisms that do not have leucine producing ability and have been given leucine producing ability. For example, a Corynebacterium microorganism having L-leucine producing ability refers to a naturally occurring microorganism itself or a Corynebacterium microorganism that has been improved in L-leucine producing ability by inserting an exogenous gene related to a leucine producing mechanism or by enhancing or inactivating the activity of an endogenous gene.

[0076] The microorganism may be a Corynebacterium sp. microorganism.

[0077] The microorganisms of the genus Corynebacterium include Corynebacterium glutamicum, Corynebacterium ammoniagenes, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium alkanolyticum, Corynebacterium callunae, Corynebacterium lilium, Corynebacterium melassecola, Corynebacterium thermoaminogenes, Corynebacterium The bacterium may be, for example, Corynebacterium thermoaminogenes, Corynebacterium efficiens, and / or Corynebacterium herculis.

[0078] The microorganism (or recombinant cell) may be any naturally occurring or artificially produced through transformation. For example, the microorganism (or recombinant cell) may be transformed with a polynucleotide encoding a mutant polypeptide according to one embodiment or a vector containing the same.

[0079] As used herein, "transformation" refers to the introduction of a gene or polynucleotide into a host cell so that it can be expressed in the host cell, and a transformed gene or polynucleotide may include, without limitation, one that is inserted into the host cell's chromosome or located extrachromosomally, so long as it can be expressed in the host cell.

[0080] As used herein, the method of transformation includes, without limitation, any method for introducing a gene into a cell, and can be carried out by selecting a suitable standard technique as known in the art depending on the host cell. For example, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, retroviral infection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and / or lithium acetate-DMSO method can be used, but are not limited thereto.

[0081] Said microorganism (or recombinant cell) may be one in which the polynucleotide sequence according to an embodiment is integrated into a chromosome. Homologous recombination, together with the use of a vector according to an embodiment, allows the exchange of a DNA fragment on a chromosome for a polynucleotide according to an embodiment transferred into the cell by the vector. For efficient recombination between the circular DNA molecule of the vector and the target DNA on the chromosome, the DNA region to be exchanged, containing the polynucleotide according to an embodiment, is provided at its ends with nucleotide sequences that are homologous to the target site; these determine the integration of the vector and the exchange site of the DNA. For example, a polynucleotide according to an embodiment may be exchanged for the native leuA gene at a native gene site in the chromosome or integrated into an additional gene site.

[0082] Another embodiment may provide a method for producing L-leucine, comprising culturing said microorganism (or recombinant cell) in a medium.

[0083] In one example, the method can additionally comprise the step of recovering L-leucine in the culture medium or in the microorganism (or recombinant cell) that has been cultured.

[0084] The culture may be carried out in a suitable medium and under suitable culture conditions known in the art, which should be adapted to meet the requirements of the particular strain in a suitable manner and may be appropriately modified by a person skilled in the art.

[0085] The culture method may include, but is not limited to, for example, batch culture, continuous culture, fed-batch culture, or a combination thereof.

[0086] The medium for culturing microorganisms (or recombinant cells) can be selected from known literature (Manual of Methods for General Bacteriology. American Society for Bacteriology. Washington DC, USA, 1981), but is not limited thereto.

[0087] According to one embodiment, the medium may contain various carbon sources, nitrogen sources and trace element components, and the recombinant cells may be cultured in a conventional medium containing appropriate carbon sources, nitrogen sources, amino acids, vitamins, etc., while adjusting temperature and / or pH, etc. Carbon sources that may be used include sugars and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch, and / or cellulose, oils and fats such as soybean oil, sunflower oil, castor oil, and / or coconut oil, fatty acids such as palmitic acid, stearic acid, and / or linolenic acid, alcohols such as glycerol and / or ethanol, and organic acids such as acetic acid. These substances may be used individually or as a mixture, but are not limited thereto. Nitrogen sources that may be used may include peptone, yeast extract, meat juice, malt extract, corn steep liquor, soybean flour, and urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, and ammonium nitrate. Nitrogen sources may also be used individually or as a mixture, but are not limited thereto. Phosphorus sources that can be used include, but are not limited to, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts. The medium may also contain metal salts such as magnesium sulfate or ferrous sulfate necessary for growth, but are not limited to these. In addition, essential growth substances such as amino acids and vitamins may be included. Appropriate precursors may also be used in the medium. The medium or individual components may be added to the culture medium in an appropriate manner during the culture process, either batchwise or continuously, but are not limited to these.

[0088] According to one embodiment, the pH of the culture solution can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid to the microorganism culture solution in an appropriate manner during the culture. Also, foam generation can be suppressed during the culture using an antifoaming agent such as fatty acid polyglycol ester. Additionally, oxygen or oxygen-containing gas (e.g., air) can be injected into the culture solution to maintain the culture solution in an aerobic state. The temperature of the culture solution can be 20°C to 45°C, 25°C to 40°C, or 30°C to 37°C. The culture period can be continued until a desired amount of useful substance (e.g., L-leucine) is obtained, and can be, for example, 10 to 160 hours.

[0089] The step of separating or recovering L-leucine from the cultured microorganism (or recombinant cell) and / or culture medium can be carried out using a suitable method known in the art depending on the culture method. For example, methods such as centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, differential dissolution (e.g., ammonium sulfate precipitation), and / or chromatography (e.g., ion exchange, affinity, hydrophobic and size exclusion) can be used, but are not limited thereto. The culture medium refers to the medium in which the microorganism (or recombinant cell) is cultured.

[0090] According to one embodiment, the step of separating or recovering L-leucine can be carried out by subjecting the culture to low speed centrifugation to remove the biomass, and then subjecting the resulting supernatant to ion exchange chromatography.

[0091] The method for producing L-leucine may additionally comprise a step of purifying L-leucine.

[0092] Another aspect can provide a composition for producing L-leucine, comprising one or more selected from the group consisting of a mutant polypeptide of the present application, a polynucleotide encoding the mutant polypeptide, a vector comprising the polynucleotide, and a microorganism of the present application (e.g., a microorganism (recombinant cell) comprising a mutant polypeptide of the present application, a polynucleotide of the present application, and / or a vector of the present application).

[0093] The compositions of the present application may additionally contain any suitable excipients that are commonly used in compositions for producing amino acids, and such excipients may be, for example, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonicity agents, but are not limited thereto.

[0094] In the composition of the present application, the mutant polypeptide, polynucleotide, vector, microorganism, medium, etc. are as described in the other embodiments above.

[0095] Yet another aspect may provide use of a mutant polypeptide of the present application, a polynucleotide encoding the mutant polypeptide, a vector comprising the polynucleotide, and / or a microorganism of the present application (e.g., a microorganism (recombinant cell) comprising a mutant polypeptide of the present application, a polynucleotide of the present application, and / or a vector of the present application) for producing L-leucine.

[0096] For the purposes of this application, the mutant polypeptides, polynucleotides, vectors, microorganisms, media, etc. are as described in the other embodiments above. Effect of the Invention

[0097] The mutant polypeptide according to one embodiment can be used to produce L-leucine in high yields. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0098] The present invention will be described in more detail with reference to the following examples, but the scope of the invention is not intended to be limited by the following examples.

[0099] Example 1. Creation of a DNA library encoding mutated isopropylmalate synthases

[0100] Example 1-1. Construction of a vector containing leuA To prepare a leuA mutation library encoding mutants having isopropyl malate synthase activity, a recombinant vector containing leuA was first constructed.

[0101] To amplify the leuA gene (SEQ ID NO: 2) encoding the wild-type Corynebacterium glutamicum-derived LeuA (2-isopropylmalate synthase) protein (SEQ ID NO: 1, Uniprot accession code: P42455), PCR was performed using the chromosome of the wild-type Corynebacterium glutamicum ATCC13032 strain as a template and primers SEQ ID NO: 7 and 8, with the following conditions repeated 25 times: denaturation at 94°C for 1 minute, binding at 58°C for 30 seconds, and polymerization with Pfu DNA polymerase at 72°C for 1 minute. The specific sequences of the primers used are listed in Table 1.

[0102] The amplified PCR product was cloned into the E. coli vector pCR2.1 using the TOPO Cloning Kit (Invitrogen) according to the manufacturer's instructions to obtain "pCR-leuA."

[0103] [Table 1]

[0104] Example 1-2. Construction of a leuA mutation library A leuA mutation library was prepared using an error-prone PCR kit (clontech Diversify® PCR Random Mutagenesis Kit) based on the vector prepared in Example 1-1. PCR reaction was performed using primers of SEQ ID NO: 7 and SEQ ID NO: 8 with pCR-leuA vector as a template under conditions where 0-3 mutations per 1000 bp would occur. Specifically, PCR reaction was performed by pre-heating at 94°C for 30 seconds, followed by repeating a cycle of 94°C for 30 seconds and 68°C for 1 minute and 30 seconds 25 times under conditions where 0-3 mutations per 1000 bp would occur. The PCR product obtained was used as a megaprimer (50~125ng) to carry out PCR reactions at 95℃ for 50 seconds, 60℃ for 50 seconds, and 68℃ for 12 minutes, which were repeated 25 times, and then treated with DpnI. The DpnI-treated PCR product was transformed into E. coli DH5α by heat shock method and smeared on LB solid medium containing kanamycin (25mg / L). 20 transformed colonies were selected, plasmids were obtained, and the base sequences were analyzed, confirming that mutations were introduced at different positions with a frequency of 2 mutations / kb. Plasmids were extracted from approximately 20,000 transformed E. coli colonies, and named the "pTOPO-leuA-library."

[0105] Example 2. Evaluation of the constructed library and selection of mutants

[0106] Example 2-1. Screening of mutant strains with increased L-leucine production The pTOPO-leuA library prepared in Example 1-2 was transformed into wild-type Corynebacterium glutamicum ATCC13032 by electroporation, and the transformed strain was smeared on a nutrient medium (Table 2) containing 25 mg / L kanamycin to select 10,000 colonies into which the mutant gene was inserted. The selected colonies were named ATCC13032 / pTOPO_leuA(mt)1 to ATCC13032 / pTOPO_leuA(mt)10,000. In order to identify colonies with increased L-leucine production among the 10,000 colonies obtained, the fermentation titer of each colony was evaluated as follows.

[0107] [Table 2]

[0108] Each colony was inoculated into a 250 ml corner baffle flask containing 25 μg / ml kanamycin in 25 ml of autoclaved production medium (Table 2) using a platinum loop, and then cultured at 30°C for 60 hours with shaking at 200 rpm. After the culture was completed, the amount of L-leucine produced was measured using a method using high performance liquid chromatography (HPLC, SHIMAZDU LC20A). Of the 10,000 colonies obtained, one strain (ATCC13032 / pTOPO_leuA(mt)5306) was selected that had the highest L-leucine production ability compared to the wild-type Corynebacterium glutamicum strain (ATCC13032). The concentration of L-leucine produced by the selected strain (ATCC13032 / pTOPO_leuA(mt)5306) is shown in Table 3 below.

[0109] [Table 3]

[0110] As shown in Table 3, the Corynebacterium glutamicum ATCC13032 / pTOPO_leuA(mt)5306 strain having a mutation in the leuA gene exhibited about 1.5 times higher L-leucine productivity than the parent strain, Corynebacterium glutamicum ATCC13032.

[0111] Example 2-2. Identification of mutations in mutant strains with increased L-leucine production To confirm the leuA gene mutation of Corynebacterium glutamicum ATCC13032 / pTOPO_leuA(mt)5306 strain, primers of SEQ ID NO:9 and SEQ ID NO:10 in Table 4 were used to denature the DNA of ATCC13032 / pTOPO_leuA(mt)5306 strain as a template at 94℃ for 5 minutes, followed by 30 cycles of 94℃ for 30 seconds, 55℃ for 30 seconds, and 72℃ for 1 minute and 30 seconds, followed by 72℃ for 5 minutes, followed by DNA sequencing.

[0112] [Table 4]

[0113] As a result of sequencing, it was confirmed that the 739th and 740th nucleotides of the leuA gene, CC, were replaced with TG in the ATCC13032 / pTOPO_leuA(mt)5306 strain. This means that the strain can encode a mutant (hereinafter, P247C) in which the 247th amino acid proline (the 212th amino acid when the LeuA protein is composed of 581 amino acids (SEQ ID NO: 16) based on a known literature, with the translation initiation codon written as 35 nucleotides after the codon, is replaced with cysteine. The amino acid sequence of the LeuA mutant (P247C) and the nucleotide sequence of the leuA mutant encoding it are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively. In the following Examples, it was attempted to confirm whether the above mutation (P247C) affects the L-leucine production amount of Corynebacterium microorganisms.

[0114] Example 3. Confirmation of L-leucine production ability of selected mutant strains

[0115] Example 3-1. Construction of an insertion vector containing a leuA mutation In this example, an insertion vector was constructed to introduce the mutation (P247C) selected by site-directed mutagenesis into a strain. PCR was performed using the primers of SEQ ID NOs: 11 and 12 and the primer pair of SEQ ID NOs: 13 and 14, with the chromosome of Corynebacterium glutamicum wild type (ATCC13032) as a template. Specifically, PCR was performed under the following conditions: denaturation at 94°C for 5 minutes, 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute and 30 seconds, followed by 5 minutes at 72°C. The specific sequences of the primers used are listed in Table 5.

[0116] [Table 5]

[0117] The resulting PCR product was digested with SmaI restriction enzyme to form a linear pDZ vector, and the terminal 15-base homologous sequence between the DNA fragments was fused and cloned using In-Fusion enzyme to create the vector "pDZ-leuA(P247C)" in which the 247th amino acid of LeuA, proline (Pro), was replaced with cysteine ​​(Cys).

[0118] Example 3-2. Introduction of a mutation into the leuA gene in the ATCC13032 strain The pDZ-leuA(P247C) vector prepared in Example 3-1 was transformed into ATCC13032 by electroporation, and a strain in which the vector was inserted into the chromosome by recombination of homologous sequences was selected in a medium containing 25 mg / L kanamycin. The selected primary strain was again subjected to a second crossover to select a strain in which a mutation was introduced into the leuA gene. The presence or absence of a mutation in the leuA gene of the final transformed strain was confirmed by performing PCR (94°C for 5 minutes, followed by 30 cycles of 94°C for 30 seconds / 55°C for 30 seconds / 72°C for 90 seconds, 72°C for 5 minutes) using primers of SEQ ID NO: 9 and SEQ ID NO: 15, followed by nucleotide sequence analysis. As a result of the base sequence analysis, it was confirmed that the leuA mutation was introduced into the strain, which encodes LeuA in which the 739th and 740th nucleotides of the leuA gene in the chromosome of the strain, CC, were replaced with TG, and the 247th amino acid, proline (Pro), was replaced with cysteine ​​(Cys). The constructed strain was named "ATCC13032_leuA_P247C". The specific sequences of the primers used are listed in Tables 4 and 6.

[0119] [Table 6]

[0120] Example 3-3. Evaluation of L-leucine production ability of mutant strains In order to evaluate the L-leucine producing ability of the ATCC13032_leuA_P247C strain prepared in Example 3-2, a flask fermentation titer evaluation was performed in the same manner as in Example 2. A loopful each of the parent strains Corynebacterium glutamicum ATCC13032 and ATCC13032_leuA_P247C was inoculated into a 250 ml corner baffle flask containing 25 ml of production medium, and L-leucine was produced by shaking at 200 rpm at 30°C for 60 hours. After the end of the cultivation, the amount of L-leucine produced was measured by HPLC, and the L-leucine concentration in the culture solution for each strain is shown in Table 7 below.

[0121] [Table 7]

[0122] As shown in Table 7, ATCC13032_leuA_P247C had an L-leucine yield that was about 1.55 times higher than that of the parent strain, Corynebacterium glutamicum ATCC13032.

[0123] Example 4. Evaluation of leucine production ability in leucine-producing mutant strains Since wild-type strains of the genus Corynebacterium produce trace amounts of L-leucine, a leucine-producing strain derived from ATCC13032 was prepared and the mutation (P247C) selected in Example 2 was introduced to confirm the L-leucine producing ability. The specific experiment is as follows.

[0124] Example 4-1. Preparation of L-leucine producing strain (CJL-8100 strain injection) As strains for producing high concentrations of L-leucine, we prepared two ATCC13032-derived strains containing (1) a mutation in which G at the 1673rd nucleotide of the leuA gene is replaced by A, resulting in the 558th amino acid, arginine, being replaced by histidine (R558H) and (2) a mutation in which GC at the 1682nd and 1683rd nucleotides of the leuA gene are replaced by AT, resulting in the 561st amino acid, glycine, being replaced by aspartic acid (G561D). Specifically, the pDZ-leuA(R558H, G561D) vector (Korea Patent Publication No. 10-2018-0077008) containing the leuA gene mutation was transformed into Corynebacterium glutamicum ATCC13032 by electroporation, and a strain in which the vector was inserted into the chromosome by recombination of homologous sequences was selected in a medium containing 25 mg / L kanamycin. The selected primary strain was then subjected to a second crossover to select a strain in which a leuA gene mutation was introduced. The final transformed strain was examined for the presence or absence of mutation by PCR (94°C for 5 minutes, followed by 30 cycles of 94°C for 30 seconds / 55°C for 30 seconds / 72°C for 90 seconds, 72°C for 5 minutes) using primers of SEQ ID NO: 7 and SEQ ID NO: 13, and the base sequence was analyzed to confirm that the R558H and G561D mutations were introduced. The specific sequences of the primers used are shown in Tables 1 and 5. The ATCC13032_leuA_(R558H, G561D) strain transformed with the pDZ-leuA(R558H, G561D) vector was named "CJL-8100."

[0125] Example 4-2. Construction of an insertion vector containing a leuA mutation In this example, we attempted to prepare an insertion vector to introduce the mutation (P247C) selected in Example 2 into CJL-8100, an L-leucine-producing strain in which two mutations (R558H, G561D) had been introduced into LeuA. PCR was carried out using the chromosome of the CJL-8100 strain as a template and the primers of SEQ ID NOs: 9 and 10, and the primer pair of SEQ ID NOs: 11 and 12. After denaturation at 94°C for 5 minutes, PCR was repeated 30 times at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute and 30 seconds, followed by polymerization reaction at 72°C for 5 minutes. The resulting PCR product was cut with SmaI restriction enzyme and cloned by fusing the terminal 15-base homologous sequence between the DNA fragments using In-Fusion enzyme to create vector pDZ-leuA (P247C, R558H, G561D) containing a leuA mutation that encodes a LeuA mutant in which the 558th amino acid, arginine, is replaced with histidine and the 561st amino acid, glycine, is replaced with aspartic acid in the wild-type LeuA amino acid sequence, and in which the 247th amino acid, proline (Pro), of LeuA is replaced with cysteine ​​(Cys).

[0126] Example 4-3. Introduction and evaluation of LeuA mutant (P247C) in CLJ-8100 strain The L-leucine producing strain CJL-8100 was transformed with the pDZ-leuA (P247C, R558H, G561D) vector prepared in Example 4-2, and the strains in which the vector was inserted into the chromosome by recombination of the homologous sequence were selected in a medium containing 25 mg / L kanamycin. The selected primary strains were again subjected to a second cross-over to select strains in which the target gene mutation was introduced. The final transformed strains were analyzed for the presence or absence of leuA gene mutation by PCR (94°C for 5 minutes, followed by 30 cycles of 94°C for 30 seconds / 55°C for 30 seconds / 72°C for 90 seconds, 72°C for 5 minutes) using primers of SEQ ID NO: 9 and SEQ ID NO: 15, followed by analysis of the base sequence. As a result of the base sequence analysis, it was confirmed that the leuA mutations encoding LeuA mutants (P247C, R558H, G561D) in which the 1673rd nucleotide of the leuA gene in the chromosome of the strain, G, is replaced by A, the 1682nd and 1683rd nucleotides, GC, are replaced by AT, and the 739th and 740th nucleotides, CC, are replaced by TG, and the 558th amino acid of the LeuA protein, arginine, is replaced by histidine, the 561st amino acid, glycine, is replaced by aspartic acid, and the 247th amino acid, proline (Pro), is replaced by cysteine ​​(Cys), were introduced into the strain. The prepared CJL8100_leuA_P247C was named "CA13-8105" and deposited with the Korean Culture Center of Microorganisms (KCCM), an international depository institution under the Budapest Treaty, on April 29, 2020 and assigned the deposit number KCCM12709P. The amino acid sequence of the LeuA mutant containing the three mutations (P247C, R558H, G561D) and the nucleotide sequence of the leuA mutant encoding the same are as shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0127] The L-leucine productivity of ATCC13032, the prepared CJL-8100, and CA13-8105 strains was evaluated. Specifically, flask culture was performed in the same manner as in Example 2-2, and after the culture was completed, the L-leucine production of the parent strain and the mutant strain was measured using HPLC, and the results are shown in Table 8.

[0128] [Table 8]

[0129] As shown in Table 8, the L-leucine producing strain Corynebacterium glutamicum CJL8100 had about 130% higher L-leucine productivity than the parent strain ATCC13032. The CA13-8105 strain, which was additionally introduced with the leuA_P247C mutation in the CJL8100 strain, had about 150% higher L-leucine productivity than the parent strain CJL8100. These results confirm that the amino acid at position 247 in the amino acid sequence of the LeuA protein is an important position for L-leucine producing activity.

[0130] Example 4-4. Measurement of isopropyl malate synthase activity in a strain into which a LeuA mutant has been introduced In order to measure the activity of isopropyl malate synthase in the L-leucine producing strains CJL-8100 and CA13-8105 prepared in Example 4-3, the following experiment was carried out.

[0131] A loopful of each of the strains (CJL-8100, CA13-8105) and wild type ATCC13032 was inoculated into a 250 ml corner baffle flask containing 25 ml of each seed medium (production medium in Table 2), and cultured at 30°C for 16 hours with shaking at 200 rpm. After the culture was completed, the culture was centrifuged, the supernatant was discarded, and the pellet was washed and turbidified with a lysis buffer solution, and the cells were disrupted using a bead-type disrupter. Protein quantification of the lysate was performed according to the Bradford method, and a lysate containing 100 μg / ml of protein was used. The activity of the isopropyl malate synthase enzyme was measured by measuring the change in absorbance at 412 nm due to the formation of thionitrobenzoate (TNB) from DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) and Ellman's reagent by reduction using the generated CoA.

[0132] The results of measuring the isopropyl malate synthase activity in each strain are shown in Table 9 below.

[0133] [Table 9]

[0134] Next, to confirm the degree of release of the feedback inhibition of the enzyme against leucine, the activity of isopropyl malate synthase was measured by measuring the amount of CoA produced when a lysate containing 100 μg / ml of protein was used under the condition that 2 g / l of leucine was added. The results of isopropyl malate synthase activity measurement for each strain are shown in Table 10 below.

[0135] [Table 10]

[0136] As shown in Tables 9 and 10, the L-leucine producing strains CJL-8100 and CA13-8105 transformed with the LeuA mutant expression vector were confirmed to have 1.13-fold and 1.21-fold increased isopropyl malate synthase activity, respectively, compared to the control Corynebacterium glutamicum ATCC 13032. In addition, the L-leucine producing strains maintained 78% and 88% of the enzyme activity of isopropyl malate synthase, respectively, even under the condition of 2 g / L leucine addition, confirming that feedback inhibition by leucine was relieved.

[0137] From the above description, a person skilled in the art to which the present application pertains can understand that the present application can be implemented in other specific forms without changing its technical ideas or essential features. In this regard, it should be understood that the above described embodiments are illustrative in all respects and are not limiting. The scope of the present application should be interpreted as including all modifications or alterations derived from the meaning and scope of the claims below, rather than the above detailed description, and their equivalent concepts.

[0138] [Accession number] Name of depository institution: Korea Microorganism Collection Center Accession number: KCCM12709P Date of acceptance: 20200429

[0139] TIFF0007584536000011.tif248169

Claims

1. A mutant polypeptide having isopropylmalate synthase activity and having 94% or more identity to the amino acid sequence of SEQ ID NO:1, A mutant polypeptide in which the proline amino acid residue at the position corresponding to the 247th amino acid in the amino acid sequence of SEQ ID NO:1 is replaced with cysteine.

2. A mutant polypeptide described in claim 1, in which the 247th proline amino acid residue in the amino acid sequence of SEQ ID NO:1 is replaced with cysteine.

3. A mutant polypeptide described in claim 1, in which the 212th proline amino acid residue in the amino acid sequence of SEQ ID NO: 16 is replaced with cysteine.

4. The mutant polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:

3.

5. The mutant polypeptide comprises: In the amino acid sequence of SEQ ID NO: 1, the 558th arginine amino acid residue is replaced with a histidine amino acid residue; In the amino acid sequence of SEQ ID NO: 1, the 561st glycine amino acid residue is replaced with an aspartic acid amino acid residue, or The mutant polypeptide of claim 1, which is further mutated by all of these.

6. The mutant polypeptide of claim 5, wherein the mutant polypeptide comprises the amino acid sequence of SEQ ID NO:

5.

7. A polynucleotide encoding the mutant polypeptide according to any one of claims 1 to 6.

8. A vector comprising the polynucleotide of claim 7.

9. A microorganism comprising at least one selected from the group consisting of a mutant polypeptide according to any one of claims 1 to 6, a polynucleotide encoding the mutant polypeptide, and a vector comprising the polynucleotide.

10. The microorganism according to claim 9, which has an ability to produce L-leucine.

11. The microorganism according to claim 9 , wherein the microorganism is a Corynebacterium sp.

12. The microorganism according to claim 11, wherein the Corynebacterium microorganism is Corynebacterium glutamicum.

13. A method for producing L-leucine, comprising a step of culturing the microorganism according to claim 9 in a medium.

14. 14. The method for producing L-leucine according to claim 13, further comprising the step of recovering L-leucine from the culture medium or the microorganism.

15. A composition for producing L-leucine, comprising one or more selected from the group consisting of a mutant polypeptide described in any one of claims 1 to 6; a polynucleotide encoding the mutant polypeptide; a vector comprising the polynucleotide; and a microorganism comprising the polypeptide, the polynucleotide, or the vector.

16. A method for producing L-leucine using one or more selected from the group consisting of a mutant polypeptide according to any one of claims 1 to 6; a polynucleotide encoding the mutant polypeptide; a vector comprising the polynucleotide; and a microorganism comprising the polypeptide, the polynucleotide, or the vector.

Citation Information

Patent Citations

  • Related gene for high-yield L-leucine, construction method for engineering bacteria and application

    CN109456987A

  • Isopropylmalate synthetase and application thereof

    CN110540976A

  • Novel isopropylmalate synthase mutant and method for producing L-leucine using the same

    JP2020503045A

  • Microorganism producing l-leucine and method for producing l-leucine using the same

    US20180251772A1